Laakmann G, Gugath M, Kuss H J, Zygan K
Psychopharmacology (Berl). 1984;82(1-2):62-7. doi: 10.1007/BF00426382.
In order to compare the effects of chlorimipramine (CI) and desimipramine (DMI) on growth hormone (GH) and on prolactin (PRL) secretion equal doses of 25 mg CI or DMI were administered i.v. to 12 healthy subjects each. In this dose, DMI, which primarily inhibits norepinephrine (NE) uptake, induced a significantly higher GH stimulation, compared to CI, whereas CI, which primarily inhibits serotonin (5-HT) uptake induced a significantly higher PRL stimulation, compared to DMI. Following DMI administration, an increase in GH (greater than 7.5 ng/ml) was found in all subjects, after CI in only about 50% of the subjects. The varying interindividual GH secretions after CI are discussed on the basis of the different plasma levels of CI and of its metabolite desmethyl-chlorimipramine (DCI), which is a NE uptake-inhibitor.
为比较氯米帕明（CI）和去甲替林（DMI）对生长激素（GH）和催乳素（PRL）分泌的影响，分别向12名健康受试者静脉注射25mg CI或DMI的等剂量药物。在此剂量下，主要抑制去甲肾上腺素（NE）摄取的DMI，与CI相比，能显著提高GH刺激水平；而主要抑制5-羟色胺（5-HT）摄取的CI，与DMI相比，能显著提高PRL刺激水平。注射DMI后，所有受试者的GH均升高（大于7.5ng/ml），注射CI后，只有约50%的受试者GH升高。基于CI及其代谢产物去甲基氯米帕明（DCI，一种NE摄取抑制剂）的不同血浆水平，讨论了CI给药后个体间GH分泌的差异。
